NEW TREATMENTS FOR PATIENTS WITH MENTAL ILLNESS
Associate Professor Bernadette Fitzgibbon
Director of Psychiatry Research
Paratus Clinical, Australia &
Associate Professor,
Australian National University, Canberra, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | November 2025
Associate Professor Bernadette Fitzgibbon is a neuroscientist with several decades of experience in researching, developing, and translating novel therapies for mental health and chronic pain conditions. This includes the application and optimisation of brain stimulation and psychedelic therapies, overseeing large multi-site intervention trials, both within Australia and abroad. Through her work, she has developed meaningful collaborations with consumers, volunteers, policy makers, and services providers, ensuring that the outcomes of her work contribute towards real-world clinical impact.
She is currently the Director of Psychiatry Research at Paratus Clinical, where she leads the delivery of clinical trials in emerging therapies for psychiatry, collaborating with academic institutions, pharmaceutical and biotechnology companies. She is also an Associate Professor at the Australian National University, where she contributes to novel investigator-initiated trials within interventional psychiatry and clinical neuroscience, and a consultant at The Psychedelic Consultancy: a hub to connect and support professionals navigate the legal psychedelic assisted psychotherapy ecosystem in Australia and internationally. Together, she is dedicated to changing the landscape of mental health treatments to improve the outcomes for people living with mental illness.
Source: Supplied
https://orcid.org/0000-0002-5339-5304
-
Life-changing donor milk for preterm babies
Dr Laura Klein is National Milk Research Leader at Australian Red Cross Lifeblood. Australian Red Cross Lifeblood is funded by Australian governments to provide life-giving blood, plasma, and transplantation and biological products.
Dr Klein works with clinicians and researchers across Australia to understand how donated breast milk can be used to improve outcomes for vulnerable babies. She’s passionate about generating evidence to improve the products and services that milk banks provide to donors and the families who receive donated breast milk.
-
Personalised approaches to lung therapy
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
-
Genetic disease research imitating function and architecture of organs
Professor Wolvetang was among the first to bring the first human embryonic stem cells to Queensland, with his Wolvetang Group at the AIBN now renowned for its work with organoids: growing them, studying them, and using them to try and understand diseases and human development.
Using cutting edge technology, Professor Wolvetang designs and grows organoids both for their own work and for labs across the country, coaxing pluripotent stem cells or tissue samples into 3D structures that mimic the function and architecture of real brains, livers, kidneys, spinal cords, and intestines.
